<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Pharmaceuticals</title>
	<atom:link href="http://www.tapanray.in/tag/pharmaceuticals/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>To Reduce Disease Burden India Launches A New Study On Access to Affordable Drugs</title>
		<link>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs</link>
		<comments>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/#comments</comments>
		<pubDate>Mon, 28 Mar 2022 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB-PMJAY]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[burden]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reduce]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10678</guid>
		<description><![CDATA[As India is struggling hard to come out of economic meltdown, and more – while navigating through the Covid-19 pandemic, the issue of reducing the National Disease Burden (NDP) with comprehensive measures resurfaces. According to a World Bank study, with ’17.5% &#8230; <a href="http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Uniting Pharma With Business Ethics: A Bridge Too Far?</title>
		<link>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=uniting-pharma-with-business-ethics-a-bridge-too-far</link>
		<comments>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/#comments</comments>
		<pubDate>Mon, 18 Feb 2019 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[promotional]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reminders]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uniting]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9414</guid>
		<description><![CDATA[Operating ethically not only is the right thing to do but also is fundamental to success in business. Poor governance and poor ethical business practices can lead to fines, public scrutiny and distrust – overshadowing good performance, destroying reputation, and &#8230; <a href="http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patients’ Trust And Pharma Remain Strange Bedfellows?</title>
		<link>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patients-trust-and-pharma-remain-strange-bedfellows</link>
		<comments>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/#comments</comments>
		<pubDate>Mon, 03 Sep 2018 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bedfellows]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[strange]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uneasy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9129</guid>
		<description><![CDATA[Like many other industries, pharmaceutical companies too often talk about improving focus on effective ‘stakeholder-relationship management’. The doctors obviously form an integral part of this process. There is nothing wrong with it. Nevertheless, serious concern of ‘conflict of interest’ between &#8230; <a href="http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Department of Pharmaceuticals On The Same Page As The Prime Minister?</title>
		<link>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister</link>
		<comments>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/#comments</comments>
		<pubDate>Sun, 14 May 2017 23:56:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMC]]></category>
		<category><![CDATA[amended]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[malevolent]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[statute]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unholy]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8225</guid>
		<description><![CDATA[“The open secret is that pharmaceutical companies throw all manners of inducements on doctors to prescribe their medicines. The victim of their misdemeanors is the unsuspecting patient. Mr. Modi clearly wants to break this self-serving chain” – highlighted a media &#8230; <a href="http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Price Negotiation For Patented Drugs: Still Continues A Policy Paralysis</title>
		<link>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=price-negotiation-for-patented-drugs-continues-a-policy-paralysis</link>
		<comments>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/#comments</comments>
		<pubDate>Mon, 12 Dec 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[policy Paralysis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8006</guid>
		<description><![CDATA[Many poor and even middle-income patients, who spend their entire life savings for treatment of life-threatening ailments, such as, cancer, have been virtually priced out of the access to patented new drugs, across the world. As articulated by the American &#8230; <a href="http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals: Still An Oasis Amidst Well-Regulated Pharmaceuticals</title>
		<link>http://www.tapanray.in/nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals</link>
		<comments>http://www.tapanray.in/nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals/#comments</comments>
		<pubDate>Sun, 27 Nov 2016 23:34:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[foods]]></category>
		<category><![CDATA[formulations]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[functional]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[nutritional]]></category>
		<category><![CDATA[Oasis]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[phytochemical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulated]]></category>
		<category><![CDATA[Space]]></category>
		<category><![CDATA[supplement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tweaking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7987</guid>
		<description><![CDATA[On November 24, 2016, the food-safety watchdog of India announced that health supplements or Nutraceuticals cannot be sold as &#8216;medicines&#8217; anymore. This new regulatory standard has been set for the manufacturers of Nutraceuticals and food supplements, and is aimed at &#8230; <a href="http://www.tapanray.in/nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Indian Drug Control World’s Weakest: Pharma Trade Bodies Working At Cross Purposes&#8217;</title>
		<link>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes</link>
		<comments>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/#comments</comments>
		<pubDate>Mon, 25 Apr 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[cross-purposes]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Edmund]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safra]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7612</guid>
		<description><![CDATA[&#8220;In the entire world, I think our drug control system probably is the weakest today. It needs to be strengthened,&#8221; said the Secretary of the Department of Pharmaceuticals (DoP) &#8211; V K Subburaj at an event in New-Delhi on April &#8230; <a href="http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ease of Doing Pharma Business in India: A Kaleidoscopic View </title>
		<link>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view</link>
		<comments>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/#comments</comments>
		<pubDate>Mon, 28 Mar 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doing]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ease]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irration]]></category>
		<category><![CDATA[Kaleidoscope]]></category>
		<category><![CDATA[Kaleidoscopic]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7552</guid>
		<description><![CDATA[Ensuring ease of doing any ethical business activity in India, is a new focus area of the Government and is very rightly so. Creating ease of doing ethical pharma business too, falls under this overall national objective. In this article, &#8230; <a href="http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>3D Printing: An Emerging Game Changer in Pharma Business</title>
		<link>http://www.tapanray.in/3d-printing-an-emerging-game-changer-in-pharma-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=3d-printing-an-emerging-game-changer-in-pharma-business</link>
		<comments>http://www.tapanray.in/3d-printing-an-emerging-game-changer-in-pharma-business/#comments</comments>
		<pubDate>Mon, 11 Jan 2016 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[3DP]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Aprecia]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[Cronin]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lee]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MIT]]></category>
		<category><![CDATA[Nanoscience and Chemical Complexity]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[printing]]></category>
		<category><![CDATA[Professor of Chemistry]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Ted]]></category>
		<category><![CDATA[video]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7393</guid>
		<description><![CDATA[On August 3, 2015, Aprecia Pharmaceuticals in the United States took a game changing step towards a new paradigm of the global pharma business. The Company  announced that for the first time ever, the U.S. Food and Drug Administration (US FDA) &#8230; <a href="http://www.tapanray.in/3d-printing-an-emerging-game-changer-in-pharma-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/3d-printing-an-emerging-game-changer-in-pharma-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Marketing Off-label Use of Drugs: A Path Much Abused?</title>
		<link>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=marketing-off-label-use-of-drugs-a-path-much-abused</link>
		<comments>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/#comments</comments>
		<pubDate>Mon, 30 Nov 2015 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abused]]></category>
		<category><![CDATA[ADE]]></category>
		<category><![CDATA[adverse]]></category>
		<category><![CDATA[cities]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Internal]]></category>
		<category><![CDATA[Italy]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[methods]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[opposes]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[records]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[smart]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[usages]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7296</guid>
		<description><![CDATA[As many would know, prescribing any medicine for disease conditions that are not approved by the drug approving authorities while granting its marketing approval, is generally termed as ‘off-label’ use of drugs. It is also a usual practice in most &#8230; <a href="http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
